Sanofi and BMS paid big money for rare disease and cancer assets, while Regeneron got in the obesity game; AstraZeneca, Gilead and Amgen shone at ASCO; RFK Jr. and the CDC appeared to disagree over ...

J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at ...

Bristol-Myers Squibb has teamed up with BioNTech to co-develop a bispecific antibody, BNT327, targeting multiple solid tumors ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

GERMAN drug developer BioNTech has signed an agreement with US pharmaceutical giant Bristol Myers Squibb (BMS) to manufacture ...

Older adults with cardiovascular disease (CVD) or CVD risk factors report that gaps in communication among their providers are common and hazardous.

"I'm honored to join the Board of Entrada as it advances its clinical-stage portfolio of Duchenne therapies and its growing ...

BioNTech saw its share prices grow by 18.05 percent on Monday to finish at $113.10 apiece following news that it joined ...

Dalton Cook had a sectional title game to remember. All the Jimtown junior did was pick-up the win on the mound, drive in three runs with three hits, including a bases-clearing double that broke the ...

Coming off the S&P 500’s best May in 35 years, the benchmark edged up at the start of what’s historically one of its quietest ...

Trump began his second term as president on Jan. 20 and opted not to enforce it. He first extended the deadline to early April, and then again last month to June 19.

CHICAGO -- The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for ...